These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9815273)

  • 21. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Jung YJ; Lee Y; Lee JS; Lee YN; Park S; Kang SM
    PLoS One; 2015; 10(10):e0139916. PubMed ID: 26468884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
    Johnson TR; Teng MN; Collins PL; Graham BS
    J Virol; 2004 Jun; 78(11):6024-32. PubMed ID: 15141000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.
    Fuentes S; Coyle EM; Golding H; Khurana S
    J Virol; 2015 Aug; 89(16):8193-205. PubMed ID: 26018164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cautionary note on experimental artefacts induced by fetal calf serum in a viral model of pulmonary eosinophilia.
    Ostler T; Ehl S
    J Immunol Methods; 2002 Oct; 268(2):211-8. PubMed ID: 12215389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R; Olszewska W; Singh M; Megede JZ; Melero JA; O'Hagan D; Openshaw PJ
    Vaccine; 2008 Feb; 26(6):753-61. PubMed ID: 18191308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.
    Srinivasa BT; Fixman ED; Ward BJ
    Eur J Immunol; 2014 Aug; 44(8):2349-59. PubMed ID: 24796717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS
    Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transfer of the enhancing effect of respiratory syncytial virus infection on subsequent allergic airway sensitization by T lymphocytes.
    Schwarze J; Mäkelä M; Cieslewicz G; Dakhama A; Lahn M; Ikemura T; Joetham A; Gelfand EW
    J Immunol; 1999 Nov; 163(10):5729-34. PubMed ID: 10553105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection.
    Cautivo KM; Bueno SM; Cortes CM; Wozniak A; Riedel CA; Kalergis AM
    J Immunol; 2010 Dec; 185(12):7633-45. PubMed ID: 21084664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.
    Tang YW; Graham BS
    J Clin Invest; 1997 May; 99(9):2183-91. PubMed ID: 9151790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells.
    de Waal L; Süzer Y; Wyatt LS; Sintnicolaas K; Sutter G; Moss B; Osterhaus AD; de Swart RL
    Viral Immunol; 2006; 19(4):669-78. PubMed ID: 17201662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins.
    Lee YT; Ko EJ; Kim KH; Hwang HS; Lee Y; Kwon YM; Kim MC; Lee YN; Jung YJ; Kang SM
    J Biomed Nanotechnol; 2017 Jan; 13(1):84-98. PubMed ID: 29302248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness.
    Schwarze J; Cieslewicz G; Joetham A; Ikemura T; Hamelmann E; Gelfand EW
    J Immunol; 1999 Apr; 162(7):4207-11. PubMed ID: 10201948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virally delivered cytokines alter the immune response to future lung infections.
    Harker J; Bukreyev A; Collins PL; Wang B; Openshaw PJ; Tregoning JS
    J Virol; 2007 Dec; 81(23):13105-11. PubMed ID: 17855518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.
    Varga SM; Wang X; Welsh RM; Braciale TJ
    Immunity; 2001 Oct; 15(4):637-46. PubMed ID: 11672545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.
    Plotnicky-Gilquin H; Huss T; Aubry JP; Haeuw JF; Beck A; Bonnefoy JY; Nguyen TN; Power UF
    Virology; 1999 May; 258(1):128-40. PubMed ID: 10329575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.